Congenital hyperinsulinism (CHI) is the most important cause of persistent hypoglycaemia in the neonate and infant. It is a clinically and genetically heterogeneous entity. The clinical heterogeneity is manifested by severity ranging from extremely severe life-threatening disease to very mild clinical symptoms which may even be difficult to identify. Furthermore, clinical responsiveness to medical and surgical management is extremely variable. Two histopathological forms have been described: a diffuse form of CHI and a focal form of CHI. Recent discoveries have begun to clarify the molecular aetiology of the disease and therefore the mechanisms responsible for its clinical heterogeneity are becoming clearer. Mutations in four different genes have been identified in patients with CHI. Most cases are caused by mutations in genes coding for either of the two subunits of the ß-cell K ATP channel (ABCC8 and KCNJ11). In the diffuse form of CHI, the hyperinsulinism is due to a recessive mutation of both alleles of these genes (rare dominant mutations have been described). In the focal form of CHI, two events intervene: first, the inheritance of a paternal ABCC8/KCNJ11 mutation; second, the focal reduction to homozygosity of the mutation during pancreatic development by a localized loss of the maternal 11p15 region. Others cases of CHI are due to rare mutations in the ß-cell enzymes glucokinase (only one family described) and glutamate dehydrogenase in hyperammonaemia-associated hyperinsulinism. However, in as many as 50% of cases, no genetic aetiology has yet been identified.
Introduction
Congenital hyperinsulinism (CHI) is a clinically and genetically heterogeneous entity, the genetics of which have only recently begun to be elucidated. Its incidence in the general population ranges from 1:3,000 in areas of high consanguinity to 1:30,000 in the West [1] . Clinical heterogeneity includes a highly variable age of onset, severity and responsiveness to medical therapy [1] . The pathological findings are also variable and two distinct histopathological forms have been described: a diffuse form and a focal form [2] . Most cases (about 60%) show diffuse involvement of the ß-cells throughout the pancreas (diffuse CHI) while some (about 40%) have focal adenomatous hyperplasia (focal CHI) in which a limited region of the pancreas appears to be involved, the remainder of the pancreas being histologically and functionally normal [2] .
Genetic heterogeneity has also been described. Mutations in four different genes have now been detected in hyperinsulinaemic patients, and both autosomal recessive and dominant inheritance have been demonstrated. However, in many cases the genetic aetiology remains unknown. In this review we will attempt to provide an updated molecular classification of CHI.
Molecular Regulation of Insulin Secretion
The normal resting cell membrane is maintained in a hyperpolarized state by the Na + ,K + -ATPase pump and the open ATP-sensitive potassium channels (K ATP channel). These channels are a link between the energetic status of the cell and the polarization of the membrane. When plasma glucose increases, it enters the cell through the specific membrane-bound glucose transporter GLUT2. It is then phosphorylated by the enzyme glucokinase and metabolized, resulting ultimately in the phosphorylation of ADP to ATP, thereby increasing the ATP/ ADP ratio [3] .
This increase causes the K ATP channels to close, which results in depolarization of the cell membrane, opening of voltage-dependent Ca 2+ channels and a rise in free intracellular Ca 2+ concentration. This, in turn, activates the insulin secretory mechanisms. Glucokinase is the ratelimiting step in the metabolism of glucose and is thus a key step in the regulation of insulin secretion [3] . The ATP/ADP ratio can be increased by metabolism of substrates other than glucose, such as amino acids. The K ATP channel can be regulated by drugs, the most common of which are the antidiabetic sulfonylureas (tolbutamide, glibenclamide, glipizide etc.), which cause closure of the channel, membrane depolarization and insulin secretion. Diazoxide has the opposite effect, increasing the channel's mean open probability, thus inhibiting insulin secretion, and is commonly used in states of unregulated insulin secretion, particularly insulinomas and some cases of CHI [3] . The K ATP channel is an octameric complex formed by four subunits of ABCC8 (SUR1, sulfonylurea receptor 1) and four subunits of KCNJ11 (K IR 6.2, potassium inward rectifier 6.2).
Mutations in four different genes involved in these pathways have been identified in CHI and now allow a molecular classification of this disease.
Mutations in the K ATP Channel Subunit Genes ABCC8-HI and KCNJ11-HI About 80 mutations of ABCC8 and 10 mutations of KCNJ11 are now known to cause CHI (Fournet et al., unpublished data). Dunne et al. [4] proved the association between ABCC8 mutations, K ATP channel function and CHI by demonstrating a lack of K ATP channel function in cells obtained at the time of pancreatectomy from a patient known to be homozygous for an SUR1 mutation.
ABCC8 mutations are spread throughout the coding region of the gene, although there is an apparent clustering of mutations in the second nucleotide binding domain (NBF2) (about 60% of the mutations). Recently, in vitro studies of how these mutations affect channel function have provided important new information about how this protein regulates channel function [5] [6] [7] . Some mutations completely eliminate channel activity, whereas others alter channel density or channel activity in response to intracellular nucleotide concentrations. A lack of response to increased MgADP concentrations appears to be a defect common to several different mutations [5] [6] [7] .
Most reported ABCC8 and KCNJ11 mutations appear to be recessive, because heterozygous parents and siblings are clinically normal. However, two dominant mutations of ABCC8 have recently been described [8, Fournet (unpublished data)]. No dominant mutation of KCNJ11 has been described, but a dominant negative KCNJ11 (K IR 6.2) mutation has been engineered into the mouse homologue of this gene.
Most of the ABCC8 and KCNJ11 mutations are extremely rare and most were found to be unique to specific families [9] . However, in the Ashkenazi Jewish population, at least 88% of the disease-associated chromosomes carry one of two specific mutations (3992-9g-a and DF1388) [10] . More recently, a founder mutation (V187D) was found in Finnish patients with CHI [11] .
Focal Forms of CHI Linked to ABCC8-KCNJ11 Mutations
Ever since CHI was initially described, there has been controversy about the histopathological findings associated with the clinical syndrome. One of the main controversies related to the existence of a group of patients in whom only a part of the pancreas is affected by so-called focal CHI [2] . Although careful histological examination did demonstrate focal CHI in some cases, the pathophysiology of the entity was not known until very recently. de Lon- Fournet/Junien lay et al. [12] reported loss of maternal chromosomal region 11p15 in the focal lesions of 10 probands with CHI. The maternal 11p15 region loss apparently occurs during development of the pancreas and affects only cells in one specific region of the gland. The precise timing and location of the somatic event determines the location and extent of the affected region [13] .
The chromosome deletion contains at least two imprinted maternally expressed genes (P57KIP2 and H19) that encode important cell cycle regulators, and an imprinted paternally expressed gene encoding a growth stimulator, IGF2 (insulin-like growth factor-II). Thus, in cells with the deleted maternal allele, the growth suppressing genes are not expressed, whereas the growth stimulating gene is normally expressed, a combination that results in abnormal proliferation of affected cells [13] . However, these patients have very severe diazoxide-unresponsive CHI, thus abnormal cell proliferation alone is not sufficient to explain the clinical phenotype. In all patients reported by de Lonlay et al. [12] , the SUR1 and K IR 6.2 loci were within the region deleted; however, there is no evidence to suggest that either of these two genes is imprinted, so alternative explanations were needed.
In 1997, Verkarre et al. [14] and Ryan et al. [15] described separately five patients with focal CHI, loss of the maternal chromosome 11p in the lesion, and a heterozygous germline mutation on the paternal SUR1 allele. Another seven patients with focal CHI, all presenting with a paternally inherited germline mutation, were subsequently identified [13] . Somatic loss of the maternal allele of chromosome 11p in a patient carrying an SUR1 mutation on the paternal allele results in reduction to hemizygosity or homozygosity for the mutant allele in the affected cells. Therefore, the cells within the focal lesion proliferate, presumably because of unbalanced production of tumour growth suppressing and growth stimulating factors, and lack functional K ATP channels. This causes unregulated insulin secretion that is unresponsive to drug treatment. Therefore, the combination of a paternally inherited SUR1 mutation, along with a second somatic event causing the loss of chromosome 11p, creates a proliferating cell population that secretes insulin in an unregulated manner, thus fully explaining the clinical phenotype of focal CHI [13] .
It is not possible to study the natural history of focal CHI directly because the definitive diagnosis of focal disease can only be made at the time of surgical resection. However, a cohort of medically treated patients was recently reported who were heterozygous for SUR1 mutations on the paternal chromosome. The unique genetic characteristics of this cohort suggested that most of the patients had focal disease. Interestingly, the patients appeared to enter clinical remission after a mean of about 16 months of medical treatment. A review of histology from three other patients with confirmed focal lesions showed increased cell apoptosis within the focal lesion. It was hypothesized that, if treated medically, focal lesions will undergo apoptosis and disappear, leaving the patient with normal cell function [16, 17] .
Glutamate Dehydrogenase (GDH)-Associated Hyperinsulinism
In 1997, Weinzimer et al. [18] described a group of patients with CHI and apparently asymptomatic hyperammonaemia. No known defects of ammonia metabolism were identified. Increased glutamate dehydrogenase (GDH) activity was found in peripheral lymphocytes from these patients and genomic mutations in the regulatory domain of the enzyme were identified [19] . About 10 mutations in this gene (GLUD1) have now been described in patients with the hyperinsulinism hyperammonaemia syndrome. Most are located in the allosteric regulatory domain of the enzyme and all are dominant mutations. Some families with multigeneration dominant inheritance have been identified, whereas the other mutations were identified as de novo mutations in affected probands. One particular mutation (S445L) appears to represent a mutation hot spot because it has been found to occur de novo in three independent cases. GDH catalyses the reversible reaction converting glutamate to ·-ketoglutarate, a substrate for the citric acid cycle in the cell. The precise mechanism by which these mutations cause the hyperinsulinism hyperammonaemia syndrome has not been confirmed; however, the known function of this enzyme has led to a plausible hypothesis, although this has yet to be tested experimentally [19] .
Increased enzyme activity might result in increased flux of amino acid substrates through ·-ketoglutarate into the citric acid cycle, resulting in increased conversion of ADP to ATP, closure of the K ATP channel, membrane depolarization and, finally, insulin secretion. This increased secretion will occur without any correlation with glucose concentrations but is triggered by high-protein diets, which increase amino acid substrate availability and therefore insulin secretion. Indeed, these patients exhibit a pronounced worsening of their hypoglycaemia after a high-protein meal and have prolonged, severe hypoglycaemia after an oral leucine load. Thus, many of these patients would have been described in the early CHI literature as having leucine-sensitive hypoglycaemia. In the liver, increased activity of this enzyme also results in increased glutamate to ·-ketoglutarate conversion, thus increasing ammonia production and decreasing glutamate concentrations. Glutamate is an essential substrate for the formation of N-acetyl glutamate (NAG), an allosteric stimulator of carbamoyl phosphate synthetase. Decreased concentrations of NAG cause decreased carbamoyl phosphate synthetase activity and accumulation of ammonia by inhibition of the urea cycle. Treatment with diazoxide is effective in most patients, consistent with the hypothesis that the defect is proximal to the K ATP channel. Recently, however, two unrelated patients with hyperinsulinism hyperammonaemia syndrome were described who had mutations in the allosteric domain of GDH and were unresponsive to diazoxide treatment (de Lonlay et al., unpublished data). This suggests that the mechanism by which GDH mutations cause hyperinsulinism might be different from that presented above [3] .
Glucokinase-Associated Hyperinsulinism
A family with a unique form of CHI with five affected individuals in three generations was described in 1998 [20] . No other case has been reported since the original publication. In a separate cohort of 30 infants with CHI, systematic screening of the entire coding sequence failed to identify any glucokinase mutations (Fournet et al., unpublished data) . Thus, we conclude that this form of CHI is probably exceedingly rare.
Genetic Counselling
In patients with ABCC8 or KCNJ11 mutations, no founder mutation has been described. Because the gene is very large (39 exons), screening of the entire coding sequence using conventional techniques is not feasible in the clinical setting. In sharp contrast, in populations in which a founder mutation is known, genetic analysis can provide very important clinical information. In the Ashkenazi Jewish population, we routinely use mutation analysis to aid the clinical diagnosis. Frequently, a genetic diagnosis can be made even before results on hormone analysis are obtained. Furthermore, genetic analysis is now routinely used for genetic counselling in this population (Fournet et al., unpublished data).
Because of the unique clinical characteristics of focal CHI described above, and because modern, non-invasive imaging techniques are not useful in diagnosing this entity, rapid genetic diagnosis would be a very valuable clinical tool. Unfortunately, because of the large number of possible mutations in the SUR1 gene, this is not yet possible in most populations. In populations with founder mutations, genetic analysis can provide evidence for, but not definitive proof of, the presence of this entity. For example, in Ashkenazi patients, if two mutant alleles are identified, or if a single mutation is identified on the maternal allele, focal CHI can be excluded. In the latter case, the presence of a novel, unidentified mutation on the paternal allele is postulated. If a single mutation is identified on the paternal allele, then focal CHI is suggested; however, given the current technology, the presence of another novel mutation on the maternal allele cannot be entirely excluded. It is in this instance that studies of the acute insulin response to different stimuli might be the key to preoperative diagnosis and could alter the management of patients (Fournet et al., unpublished data) .
Conclusion
CHI is a genetically heterogeneous entity. During the past 3 years major advances have been made in our understanding of the molecular genetic aetiology of this syndrome. Although these discoveries have provided important new information about cell physiology, the clinical usefulness of the findings is limited. A molecular classification of CHI can now be proposed.
However, in some situations, the recent discoveries have already been translated into clinically useful tests providing rapid clinical diagnosis and providing the basis for more precise genetic counselling.
In as many as 50% of CHI patients, no mutation can be found in the coding regions of ABCC8 and KCNJ11. The genetic diagnosis in these cases remains unknown.
